Invenra is focused on developing the next generation of best-in-class biologics, with an emphasis on multispecific antibodies and their derivatives. Invenra's proprietary technologies combine our highly developable B-Body™ bispecific platform with high throughput functional screening, enabling the optimization of unprecedented numbers of bispecific antibodies in phenotypic assays. Invenra has a pipeline of immuno-oncology bispecific antibodies that are currently in preclinical studies.
Location: United States, Wisconsin, Madison
Member count: 11-50
Founded date: 2011
Investors 2
| Date | Name | Website |
| - | Rose Ventu... | roseventur... |
| - | New Capita... | newcapital... |
Mentions in press and media 2
| Date | Title | Description | Category | Author | Source |
| 27.02.2013 | Quiet Wisc... | According to its website, Inve... | - | - | medcitynew... |
| - | Quiet Wisc... | Biologic drugs are filling the... | - | - | medcitynew... |